Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eastern Cooperative Oncology Group
UNC Lineberger Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Mayo Clinic
Emory University
Ohio State University Comprehensive Cancer Center
National Medical Research Radiological Centre of the Ministry of Health of Russia
NRG Oncology
University of California, San Diego
Sir Mortimer B. Davis - Jewish General Hospital
Washington University School of Medicine
Centre hospitalier de l'Université de Montréal (CHUM)
University of Utah
Sun Yat-sen University
University of Leipzig
Henan Cancer Hospital
Eastern Cooperative Oncology Group
Fudan University
George Washington University
Celldex Therapeutics
Fudan University
Abramson Cancer Center at Penn Medicine
Fudan University
Memorial Sloan Kettering Cancer Center
Nova Scotia Health Authority
University of Texas Southwestern Medical Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Iowa
Dana-Farber Cancer Institute
Icahn School of Medicine at Mount Sinai
Azienda USL 4 Prato
Burzynski Research Institute
University of Zurich
Roswell Park Cancer Institute
University of Michigan Rogel Cancer Center
University of Leipzig
University of Alabama at Birmingham
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Chicago
National Cancer Institute (NCI)
Heidelberg University
Roswell Park Cancer Institute
Fundacion Miguel Servet
Groupe Oncologie Radiotherapie Tete et Cou
National Cancer Institute (NCI)